PDF(Sci-hub)
Abstract：
Serological weak D is a reaction of 2+ or less to anti-D reagent and includes weak D and partial D phenotypes. Although identifying the RhD subtype is important for transfusion safety, serological tests are insufficient for defining the RhD subtype, and molecular tests are needed. To analyze the molecular characteristics of D variants in Koreans to facilitate the formulation of individualized transfusion strategies, molecular tests such as RhD genotyping using real-time polymerase chain reaction (PCR) and partial-D and/or weak-D sequence-specific amplification (SSP) were performed on 105 Korean Rare Blood Program (KRBP) patients exhibiting serological weak D. In total, 58 out of 68 serologically determined weak D KRBP patients were typed as having weak D or partial D phenotypes via RhD genotyping. In detail, eight (13.8%) were typed as partial DVa or DBS, nine (15.5%) as weak D type 15, and four others (6.8%) as partial DVI, partial DVII, weak D type 2, or weak D type 41 or 45, whereas the rest (n = 37, 63.8%) was typed as having either weak D or partial D. This suggests that serological weak D Koreans who require transfusion should be treated as D-negative.
摘要：
血清学弱D是2+或更少的抗D试剂的反应,并且包括弱D和部分D表型。尽管确定RhD亚型对输血安全很重要，血清学测试不足以定义RhD亚型，需要分子测试。分析韩国人D变异的分子特征，以利于制定个体化输血策略。对105名表现出血清学弱D的韩国稀有血液计划（KRBP）患者进行了分子测试，例如使用实时聚合酶链反应（PCR）和部分D和/或弱D序列特异性扩增（SSP）的RhD基因分型。通过RhD基因分型，在68例血清学确定的弱DKRBP患者中，有58例被分型为具有弱D或部分D表型。详细来说,八位(13.8%)被键入为部分DVa或DBS，9人(15.5%)为弱D型15，另外4人(6.8%)为部分DVI，部分DVII，弱D型2，或弱D型41或45，而其余（n=37，63.8％）被分型为具有弱D或部分D。这表明需要输血的血清学弱D韩国人应被视为D阴性。
